A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2018
At a glance
- Drugs Remlarsen (Primary)
- Indications Fibrosis; Keloids
- Focus Adverse reactions; Therapeutic Use
- Sponsors miRagen Therapeutics
- 07 Nov 2018 According to a miRagen Therapeutics media release, the company expects to report data from this clinical trial in the second half of 2019.
- 13 Jul 2018 Planned number of patients changed to 12.
- 10 Jul 2018 Status changed from planning to recruiting, according to a miRagen Therapeutics media release.